Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04607148 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT04607148 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 144 participants.
The verdict
NCT04607148, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study (NCT03972709/GR40973).
Interventions
- DRUG Galegenimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2022-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04607148
The ClinicalTrials.gov registry entry for NCT04607148 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galegenimab is the first listed.
NCT04607148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04607148 about?
NCT04607148 is a clinical study titled "A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who compl...
What is the current status of trial NCT04607148?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2020-11-16. Estimated completion is 2022-11-14.
What interventions are being tested in trial NCT04607148?
The interventions under investigation include: Galegenimab (DRUG).
Who is sponsoring clinical trial NCT04607148?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.